{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:22:58Z","timestamp":1788880978484,"version":"build-2803163510"},"reference-count":260,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.semcancer.2023.03.009","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T02:55:05Z","timestamp":1680231305000},"page":"84-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Epigenomic machinery regulating pediatric AML: Clonal expansion mechanisms, therapies, and future perspectives"],"prefix":"10.1016","volume":"92","author":[{"given":"Ugo","family":"Chianese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Papulino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wout","family":"Megchelenbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Tambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Altucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/bjh.16365","article-title":"AML - a signature disease in haematology","volume":"188","author":"Hokland","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.semcancer.2023.03.009_bib2","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/bloodadvances.2019001181","article-title":"Single-cell mutational profiling enhances the clinical evaluation of AML MRD","volume":"4","author":"Ediriwickrema","year":"2020","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1053\/j.seminoncol.2008.04.008","article-title":"Epigenetics in acute myeloid leukemia","volume":"35","author":"Plass","year":"2008","journal-title":"Semin Oncol."},{"key":"10.1016\/j.semcancer.2023.03.009_bib4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3389\/fped.2019.00463","article-title":"Targeted therapies for pediatric AML: gaps and perspective","volume":"7","author":"Lonetti","year":"2019","journal-title":"Front Pedia"},{"key":"10.1016\/j.semcancer.2023.03.009_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/ijms21176251","article-title":"Insights on the Interplay between Cells Metabolism and Signaling: A Therapeutic Perspective in Pediatric Acute Leukemias","volume":"21","author":"Anselmi","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-017-0416-0","article-title":"Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia","volume":"10","author":"Hackl","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2023.03.009_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","article-title":"The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML","volume":"20","author":"Vetrie","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2023.03.009_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/ajco.13367","article-title":"Genetic aberrations involved in relapse of pediatric acute myeloid leukemia: A literature review","volume":"17","author":"Zafar","year":"2021","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/BS9.0000000000000020","article-title":"Molecular mechanisms for stemness maintenance of acute myeloid leukemia stem cells","volume":"1","author":"Wang","year":"2019","journal-title":"Blood Sci."},{"issue":"35","key":"10.1016\/j.semcancer.2023.03.009_bib11","doi-asserted-by":"crossref","first-page":"56746","DOI":"10.18632\/oncotarget.10778","article-title":"Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing","volume":"7","author":"Masetti","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2023.03.009_bib12","article-title":"The epigenetic landscape of acute myeloid leukemia","volume":"2014","author":"Conway O'Brien","year":"2014","journal-title":"Adv. Hematol."},{"key":"10.1016\/j.semcancer.2023.03.009_bib13","first-page":"7","article-title":"Imetelstat induces leukemia stem cell death in pediatric acute myeloid leukemia patient-derived xenografts","volume":"11","author":"Barwe","year":"2022","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.semcancer.2023.03.009_bib14","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1126\/science.aal2380","article-title":"Epigenetic plasticity and the hallmarks of cancer","volume":"357","author":"Flavahan","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2023.03.009_bib15","first-page":"13","article-title":"Exploiting clonal evolution to improve the diagnosis and treatment efficacy prediction in pediatric AML","author":"Bertuccio","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.semcancer.2023.03.009_bib16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.exphem.2015.05.008","article-title":"Insights into cell ontogeny, age, and acute myeloid leukemia","volume":"43","author":"Chaudhury","year":"2015","journal-title":"Exp. Hematol."},{"issue":"13","key":"10.1016\/j.semcancer.2023.03.009_bib17","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1182\/blood-2008-08-077941","article-title":"Stem cell concepts renew cancer research","volume":"112","author":"Dick","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semcancer.2023.03.009_bib18","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1084\/jem.20151775","article-title":"Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage","volume":"213","author":"Quek","year":"2016","journal-title":"J. Exp. Med"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib19","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1038\/s41467-018-07584-1","article-title":"Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias","volume":"9","author":"Chaudhury","year":"2018","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1053\/j.seminhematol.2013.09.003","article-title":"Somatic characterization of pediatric acute myeloid leukemia using next-generation sequencing","volume":"50","author":"Schuback","year":"2013","journal-title":"Semin Hematol."},{"key":"10.1016\/j.semcancer.2023.03.009_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/jcm11030504","article-title":"Pediatric acute myeloid leukemia-past, present, and future","volume":"11","author":"Reinhardt","year":"2022","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.semcancer.2023.03.009_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/ijms23041968","article-title":"Straight to the point-the novel strategies to cure pediatric AML","volume":"23","author":"Lejman","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2023.03.009_bib23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3389\/fped.2019.00401","article-title":"Pediatric acute myeloid leukemia (AML): from genes to models toward targeted therapeutic intervention","volume":"7","author":"Mercher","year":"2019","journal-title":"Front Pedia"},{"key":"10.1016\/j.semcancer.2023.03.009_bib24","first-page":"12","article-title":"Cytogenetics of pediatric acute myeloid leukemia: a review of the current knowledge","author":"Quessada","year":"2021","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib25","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41467-022-29336-y","article-title":"Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2023.03.009_bib26","first-page":"11","article-title":"Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia","author":"Padella","year":"2019","journal-title":"Cancers"},{"issue":"4 Suppl","key":"10.1016\/j.semcancer.2023.03.009_bib27","first-page":"25","article-title":"Current views of chromosomal abnormalities in pediatric acute myeloid leukemia (AML)","volume":"21","author":"Shi","year":"2017","journal-title":"Eur. Rev. Med Pharmacol. Sci."},{"key":"10.1016\/j.semcancer.2023.03.009_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/asheducation-2004.1.80","article-title":"The molecular basis of leukemia","author":"Gilliland","year":"2004","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.semcancer.2023.03.009_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2020.11.005","article-title":"The RUNX1\/RUNX1T1 network: translating insights into therapeutic options","volume":"94","author":"Swart","year":"2021","journal-title":"Exp. Hematol."},{"issue":"8","key":"10.1016\/j.semcancer.2023.03.009_bib30","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1038\/leu.2012.49","article-title":"Depletion of RUNX1\/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding","volume":"26","author":"Ptasinska","year":"2012","journal-title":"Leukemia"},{"issue":"6043","key":"10.1016\/j.semcancer.2023.03.009_bib31","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1126\/science.1201662","article-title":"The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation","volume":"333","author":"Wang","year":"2011","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.semcancer.2023.03.009_bib32","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.1128\/MCB.18.12.7185","article-title":"Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO","volume":"18","author":"Gelmetti","year":"1998","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.semcancer.2023.03.009_bib33","first-page":"12","article-title":"DNA methylation signatures predict cytogenetic subtype and outcome in pediatric acute myeloid leukemia (AML)","author":"Krali","year":"2021","journal-title":"Genes"},{"issue":"7","key":"10.1016\/j.semcancer.2023.03.009_bib34","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1182\/blood.V83.7.1750.1750","article-title":"Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia","volume":"83","author":"Claxton","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2023.03.009_bib35","article-title":"CBFB-MYH11 fusion sequesters RUNX1 in cytoplasm to prevent DNMT3A recruitment to target genes in AML","volume":"9","author":"Liu","year":"2021","journal-title":"Front Cell Dev. Biol."},{"issue":"9","key":"10.1016\/j.semcancer.2023.03.009_bib36","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V85.9.2289.bloodjournal8592289","article-title":"Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia","volume":"85","author":"Liu","year":"1995","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semcancer.2023.03.009_bib37","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/leu.2010.22","article-title":"AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions","volume":"24","author":"Haferlach","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2023.03.009_bib38","first-page":"12","article-title":"DNA methylation clusters and their relation to cytogenetic features in pediatric AML","author":"Lamba","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.semcancer.2023.03.009_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138782","article-title":"Transcriptome profiling of pediatric core binding factor AML","volume":"10","author":"Hsu","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrc3877","article-title":"The RUNX family: developmental regulators in cancer","volume":"15","author":"Ito","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib41","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1038\/s41598-018-23863-9","article-title":"Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia","volume":"8","author":"Stockard","year":"2018","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.semcancer.2023.03.009_bib42","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1038\/leu.2017.45","article-title":"ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition","volume":"31","author":"Ju","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.semcancer.2023.03.009_bib43","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1097-2765(02)00740-2","article-title":"ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation","volume":"10","author":"Nakamura","year":"2002","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib44","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1128\/MCB.23.1.186-194.2003","article-title":"Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization","volume":"23","author":"Hsieh","year":"2003","journal-title":"Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.semcancer.2023.03.009_bib45","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/leu.2011.90","article-title":"The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia","volume":"25","author":"Balgobind","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12185-016-2118-8","article-title":"SET\/MLL family proteins in hematopoiesis and leukemia","volume":"105","author":"Yang","year":"2017","journal-title":"Int J. Hematol."},{"issue":"10","key":"10.1016\/j.semcancer.2023.03.009_bib47","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3324\/haematol.2010.038976","article-title":"Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia","volume":"96","author":"Balgobind","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib48","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.semcancer.2023.03.009_bib49","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1534-5807(04)00061-9","article-title":"Definitive hematopoiesis requires the mixed-lineage leukemia gene","volume":"6","author":"Ernst","year":"2004","journal-title":"Dev. Cell"},{"issue":"10","key":"10.1016\/j.semcancer.2023.03.009_bib50","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1128\/MCB.01742-12","article-title":"Quantitative dissection and stoichiometry determination of the human SET1\/MLL histone methyltransferase complexes","volume":"33","author":"van Nuland","year":"2013","journal-title":"Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.semcancer.2023.03.009_bib51","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","article-title":"Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study","volume":"114","author":"Balgobind","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semcancer.2023.03.009_bib52","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/leu.2013.90","article-title":"High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia","volume":"27","author":"Grossmann","year":"2013","journal-title":"Leukemia"},{"issue":"42","key":"10.1016\/j.semcancer.2023.03.009_bib53","doi-asserted-by":"crossref","first-page":"26340","DOI":"10.1073\/pnas.2014732117","article-title":"Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23\/KMT2A","volume":"117","author":"Bill","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7696","key":"10.1016\/j.semcancer.2023.03.009_bib54","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature25795","article-title":"Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours","volume":"555","author":"Ma","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib55","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/leu.2016.361","article-title":"NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group","volume":"31","author":"Bisio","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.semcancer.2023.03.009_bib56","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/leu.2016.267","article-title":"NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis","volume":"31","author":"Struski","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib57","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000031","article-title":"Molecular profiling defines distinct prognostic subgroups in childhood AML: a report from the french ELAM02 study group","volume":"2","author":"Marceau-Renaut","year":"2018","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib58","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng0296-154","article-title":"Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia","volume":"12","author":"Nakamura","year":"1996","journal-title":"Nat. Genet"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib59","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/ng0296-159","article-title":"The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9","volume":"12","author":"Borrow","year":"1996","journal-title":"Nat. Genet"},{"issue":"13","key":"10.1016\/j.semcancer.2023.03.009_bib60","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1182\/blood-2011-04-346643","article-title":"NUP98\/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern","volume":"118","author":"Hollink","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semcancer.2023.03.009_bib61","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/ncb1608","article-title":"NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis","volume":"9","author":"Wang","year":"2007","journal-title":"Nat. Cell Biol."},{"issue":"24","key":"10.1016\/j.semcancer.2023.03.009_bib62","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/cncr.30220","article-title":"Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups","volume":"122","author":"Creutzig","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib63","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/ped.12865","article-title":"Acute myeloid leukemia in children: Current status and future directions","volume":"58","author":"Taga","year":"2016","journal-title":"Pedia Int"},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.12.011","article-title":"Outcomes in Adult Acute Promyelocytic Leukemia: A Decade Experience","volume":"20","author":"Yedla","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/geno.1995.1008","article-title":"Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation","volume":"27","author":"Chissoe","year":"1995","journal-title":"Genomics"},{"issue":"7","key":"10.1016\/j.semcancer.2023.03.009_bib66","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.semcancer.2023.03.009_bib67","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib68","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/10428194.2012.701739","article-title":"Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia","volume":"54","author":"Konoplev","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.semcancer.2023.03.009_bib69","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcancer.2023.03.009_bib70","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.leukres.2003.10.027","article-title":"Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature","volume":"28","author":"Keung","year":"2004","journal-title":"Leuk. Res"},{"issue":"8","key":"10.1016\/j.semcancer.2023.03.009_bib71","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00277-016-2721-z","article-title":"BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features","volume":"95","author":"Neuendorff","year":"2016","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib72","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.12301","article-title":"Does BCR\/ABL1 positive acute myeloid leukaemia exist?","volume":"161","author":"Nacheva","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"44","key":"10.1016\/j.semcancer.2023.03.009_bib73","article-title":"Primary Philadelphia chromosome positive acute myeloid leukemia: A case report","volume":"97","author":"Shao","year":"2018","journal-title":"Med. (Baltim. )"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib74","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: prognostic and therapeutic implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"12","key":"10.1016\/j.semcancer.2023.03.009_bib75","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1158\/0008-5472.CAN-15-3278","article-title":"DNA methylation in cancer and aging","volume":"76","author":"Klutstein","year":"2016","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.semcancer.2023.03.009_bib76","first-page":"443","article-title":"DNA methylation dynamics in cellular commitment and differentiation","volume":"15","author":"Suelves","year":"2016","journal-title":"Brief. Funct. Genom."},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib77","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.16361","article-title":"Epigenetics of paediatric acute myeloid leukaemia","volume":"188","author":"Jones","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2023.03.009_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/epigenomes4010003","article-title":"Epigenetic modulation of self-renewal capacity of leukemic stem cells and implications for chemotherapy","volume":"4","author":"Momparler","year":"2020","journal-title":"Epigenomes"},{"issue":"42","key":"10.1016\/j.semcancer.2023.03.009_bib79","doi-asserted-by":"crossref","first-page":"26711","DOI":"10.18632\/oncotarget.25475","article-title":"Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia","volume":"9","author":"Lamba","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.semcancer.2023.03.009_bib80","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1093\/carcin\/bgm206","article-title":"Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state","volume":"28","author":"Kanai","year":"2007","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib81","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib82","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/pbc.23179","article-title":"Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group","volume":"57","author":"Ho","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2023.03.009_bib83","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41375-018-0187-9","article-title":"Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia","volume":"32","author":"Bond","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.semcancer.2023.03.009_bib84","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2012.16","article-title":"A somatic EZH2 mutation in childhood acute myeloid leukemia","volume":"26","author":"Ernst","year":"2012","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.semcancer.2023.03.009_bib85","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.leukres.2013.07.032","article-title":"DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients","volume":"37","author":"Shivarov","year":"2013","journal-title":"Leuk. Res"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib86","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/leu.2012.168","article-title":"Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report","volume":"27","author":"Ostronoff","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.semcancer.2023.03.009_bib87","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nrc3895","article-title":"DNMT3A in haematological malignancies","volume":"15","author":"Yang","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"14","key":"10.1016\/j.semcancer.2023.03.009_bib88","doi-asserted-by":"crossref","first-page":"14677","DOI":"10.18632\/aging.103520","article-title":"Expression and prognosis analysis of DNMT family in acute myeloid leukemia","volume":"12","author":"Zhang","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.semcancer.2023.03.009_bib89","first-page":"379","article-title":"18 FDG-PET\/CT: 21st century approach to leukemic tumors in 124 cases","volume":"91","author":"Cunningham","year":"2016"},{"issue":"10","key":"10.1016\/j.semcancer.2023.03.009_bib90","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood-2014-02-554204","article-title":"A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semcancer.2023.03.009_bib91","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/bloodadvances.2021005381","article-title":"Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia","volume":"6","author":"Yamato","year":"2022","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.semcancer.2023.03.009_bib92","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.leu.2402834","article-title":"Downing J.R. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23)","volume":"17","author":"Lorsbach","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib93","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.semcancer.2023.03.009_bib94","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jfma.2015.08.002","article-title":"Tet oncogene family member 2 gene alterations in childhood acute myeloid leukemia","volume":"115","author":"Li","year":"2016","journal-title":"J. Formos. Med Assoc."},{"key":"10.1016\/j.semcancer.2023.03.009_bib95","doi-asserted-by":"crossref","DOI":"10.1177\/1533033820945815","article-title":"Long noncoding RNA maternally expressed gene 3 is downregulated, and its insufficiency correlates with poor-risk stratification, worse treatment response, as well as unfavorable survival data in patients with acute myeloid leukemia","volume":"19","author":"He","year":"2020","journal-title":"Technol. Cancer Res Treat."},{"issue":"8","key":"10.1016\/j.semcancer.2023.03.009_bib96","first-page":"983","article-title":"Establishment and validation of prognosis predictive model using m(6)A RNA methylation regulators in children acute myeloid leukemia","volume":"55","author":"Xu","year":"2021","journal-title":"Zhonghua Yu Fang. Yi Xue Za Zhi"},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib97","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib98","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat. Rev. Genet"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib99","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0959-437X(00)00173-8","article-title":"Histone acetyltransferases: function, structure, and catalysis","volume":"11","author":"Marmorstein","year":"2001","journal-title":"Curr. Opin. Genet Dev."},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12943-020-01182-w","article-title":"Correction to: Role of HDACs in normal and malignant hematopoiesis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2023.03.009_bib101","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.semcancer.2023.03.009_bib102","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fonc.2019.00432","article-title":"Intersection of epigenetic and metabolic regulation of histone modifications in acute myeloid leukemia","volume":"9","author":"Dhall","year":"2019","journal-title":"Front Oncol."},{"issue":"12","key":"10.1016\/j.semcancer.2023.03.009_bib103","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1016\/j.febslet.2010.04.002","article-title":"The molecular signature of oncofusion proteins in acute myeloid leukemia","volume":"584","author":"Martens","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.semcancer.2023.03.009_bib104","article-title":"The roles of histone deacetylases and their inhibitors in cancer therapy","volume":"8","author":"Li","year":"2020","journal-title":"Front Cell Dev. Biol."},{"issue":"10","key":"10.1016\/j.semcancer.2023.03.009_bib105","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017138","article-title":"Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells","volume":"6","author":"Xu","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.semcancer.2023.03.009_bib107","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-488114","article-title":"Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors","volume":"123","author":"Bots","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semcancer.2023.03.009_bib108","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.stem.2015.08.004","article-title":"HDAC8 inhibition specifically targets Inv(16) acute myeloid leukemic stem cells by restoring p53 acetylation","volume":"17","author":"Qi","year":"2015","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib109","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/sj.cdd.4401567","article-title":"Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1\/WAF1 expression, independent of histone deacetylase 1","volume":"12","author":"Huang","year":"2005","journal-title":"Cell Death Differ."},{"issue":"7330","key":"10.1016\/j.semcancer.2023.03.009_bib110","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2023.03.009_bib111","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fcell.2019.00207","article-title":"Epigenetic therapies for acute myeloid leukemia and their immune-related effects","volume":"7","author":"Gambacorta","year":"2019","journal-title":"Front Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.semcancer.2023.03.009_bib112","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.gendis.2015.04.001","article-title":"Bmi-1: At the crossroads of physiological and pathological biology","volume":"2","author":"Bhattacharya","year":"2015","journal-title":"Genes Dis."},{"key":"10.1016\/j.semcancer.2023.03.009_bib113","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fonc.2018.00041","article-title":"Epigenetic regulators in the development, maintenance, and therapeutic targeting of acute myeloid leukemia","volume":"8","author":"Sun","year":"2018","journal-title":"Front Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2023.03.009_bib114","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat. Genet"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11912-020-01009-3","article-title":"Acute myeloid leukemia in children: emerging paradigms in genetics and new approaches to therapy","volume":"23","author":"Conneely","year":"2021","journal-title":"Curr. Oncol. Rep."},{"issue":"11","key":"10.1016\/j.semcancer.2023.03.009_bib116","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/sj.leu.2403492","article-title":"PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group","volume":"18","author":"Loh","year":"2004","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib117","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hon.2951","article-title":"CEBPA are independent good prognostic factors in pediatric acute myeloid leukemia","volume":"40","author":"Liao","year":"2022","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2023.03.009_bib118","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.leukres.2017.12.001","article-title":"Whole exome sequencing identifies novel mutations of epigenetic regulators in chemorefractory pediatric acute myeloid leukemia","volume":"65","author":"Zhan","year":"2018","journal-title":"Leuk. Res"},{"issue":"11","key":"10.1016\/j.semcancer.2023.03.009_bib119","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2015-01-621870","article-title":"Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition","volume":"126","author":"Jacque","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semcancer.2023.03.009_bib120","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood-2018-03-837468","article-title":"Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis","volume":"132","author":"Pronier","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semcancer.2023.03.009_bib121","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.molcel.2004.05.009","article-title":"Hierarchical recruitment of polycomb group silencing complexes","volume":"14","author":"Wang","year":"2004","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib122","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2019.03.011","article-title":"Molecular mechanisms directing PRC2 recruitment and H3K27 methylation","volume":"74","author":"Laugesen","year":"2019","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.semcancer.2023.03.009_bib123","doi-asserted-by":"crossref","first-page":"590","DOI":"10.4161\/epi.5.7.12558","article-title":"Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia","volume":"5","author":"Griffiths","year":"2010","journal-title":"Epigenetics"},{"key":"10.1016\/j.semcancer.2023.03.009_bib124","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/ijms20184576","article-title":"Aberrant DNA methylation in acute myeloid leukemia and its clinical implications","volume":"20","author":"Yang","year":"2019","journal-title":"Int J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.semcancer.2023.03.009_bib125","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/febs.13142","article-title":"Epigenetic alterations in acute myeloid leukemias","volume":"282","author":"Mehdipour","year":"2015","journal-title":"FEBS J."},{"key":"10.1016\/j.semcancer.2023.03.009_bib126","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fgene.2019.00133","article-title":"Epigenetic modifications in acute myeloid leukemia: prognosis, treatment, and heterogeneity","volume":"10","author":"Goldman","year":"2019","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib127","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1158\/0008-5472.CAN-16-1386","article-title":"Mutational landscape and gene expression patterns in adult acute myeloid leukemias with monosomy 7 as a sole abnormality","volume":"77","author":"Eisfeld","year":"2017","journal-title":"Cancer Res"},{"issue":"26","key":"10.1016\/j.semcancer.2023.03.009_bib128","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/blood-2018-04-844746","article-title":"Puzzling pieces of chromosome 7 loss or deletion","volume":"131","author":"Schneider","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semcancer.2023.03.009_bib129","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/17474086.2019.1657400","article-title":"Trisomy 8 in acute myeloid leukemia","volume":"12","author":"Hemsing","year":"2019","journal-title":"Expert Rev. Hematol."},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3324\/haematol.2021.280250","article-title":"Analysis of rare driving events in pediatric acute myeloid leukemia","volume":"108","author":"Noort","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib131","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.2011.08911.x","article-title":"TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele","volume":"156","author":"Bacher","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2023.03.009_bib132","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.exphem.2020.04.007","article-title":"Epigenetic regulation of protein translation in KMT2A-rearranged AML","volume":"85","author":"Lenard","year":"2020","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.semcancer.2023.03.009_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.714768","article-title":"From junk to function: LncRNAs in CNS health and disease","volume":"14","author":"Policarpo","year":"2021","journal-title":"Front Mol. Neurosci."},{"key":"10.1016\/j.semcancer.2023.03.009_bib134","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/biom11111665","article-title":"LncRNAs: novel biomarkers for pancreatic cancer","volume":"11","author":"Ghafouri-Fard","year":"2021","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib135","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ncrna.2022.02.004","article-title":"Long noncoding RNAs as promising biomarkers in cancer","volume":"7","author":"Beylerli","year":"2022","journal-title":"Noncoding RNA Res"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib136","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40348-022-00142-2","article-title":"Long noncoding RNAs as regulators of pediatric acute myeloid leukemia","volume":"9","author":"Neyazi","year":"2022","journal-title":"Mol. Cell Pedia"},{"issue":"35","key":"10.1016\/j.semcancer.2023.03.009_bib137","article-title":"Prognostic significance of long non coding maternally expressed gene 3 in pediatric acute myeloid leukemia","volume":"100","author":"Xue","year":"2021","journal-title":"Med. (Baltim. )"},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib138","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/ijlh.13225","article-title":"LncRNA MEG3 contributes to drug resistance in acute myeloid leukemia by positively regulating ALG9 through sponging miR-155","volume":"42","author":"Yu","year":"2020","journal-title":"Int J. Lab Hematol."},{"issue":"12","key":"10.1016\/j.semcancer.2023.03.009_bib139","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1038\/leu.2017.116","article-title":"Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways","volume":"31","author":"Lyu","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.semcancer.2023.03.009_bib140","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bbrc.2007.03.200","article-title":"Coordinated expression of ncRNAs and HOX mRNAs in the human HOXA locus","volume":"357","author":"Sasaki","year":"2007","journal-title":"Biochem Biophys. Res Commun."},{"issue":"8","key":"10.1016\/j.semcancer.2023.03.009_bib141","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","article-title":"Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells","volume":"98","author":"Guzman","year":"2001","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.semcancer.2023.03.009_bib142","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1182\/bloodadvances.2019032029","article-title":"The stem cell-specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia","volume":"3","author":"Al-Kershi","year":"2019","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.semcancer.2023.03.009_bib143","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/sj.leu.2402641","article-title":"Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts","volume":"16","author":"Baumgartner","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2023.03.009_bib144","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/pharmaceutics13101681","article-title":"Development of siRNA-loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a novel and safe therapeutic approach for t(8;21) pediatric acute myeloid leukemia","volume":"13","author":"Connerty","year":"2021","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.semcancer.2023.03.009_bib145","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1038\/sj.leu.2404961","article-title":"Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia","volume":"21","author":"Tonks","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.semcancer.2023.03.009_bib146","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3317","article-title":"lncRNA FBXL19-AS1 is a diagnosis biomarker for paediatric patients with acute myeloid leukemia","volume":"23","author":"Sheng","year":"2021","journal-title":"J. Gene Med"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib147","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbrc.2017.05.008","article-title":"Long non-coding RNA FBXL19-AS1 plays oncogenic role in colorectal cancer by sponging miR-203","volume":"488","author":"Shen","year":"2017","journal-title":"Biochem Biophys. Res Commun."},{"issue":"11","key":"10.1016\/j.semcancer.2023.03.009_bib148","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/abbs\/gmz110","article-title":"FBXL19-AS1 promotes cell proliferation and inhibits cell apoptosis via miR-876-5p\/FOXM1 axis in breast cancer","volume":"51","author":"Dong","year":"2019","journal-title":"Acta Biochim Biophys. Sin."},{"key":"10.1016\/j.semcancer.2023.03.009_bib149","doi-asserted-by":"crossref","DOI":"10.1177\/1533033820965580","article-title":"Oncogenic long noncoding RNA DARS-AS1 in childhood acute myeloid leukemia by binding to microRNA-425","volume":"19","author":"Dou","year":"2020","journal-title":"Technol. Cancer Res Treat."},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13046-018-0991-0","article-title":"FXR1 promotes the malignant biological behavior of glioma cells via stabilizing MIR17HG","volume":"38","author":"Cao","year":"2019","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.semcancer.2023.03.009_bib151","first-page":"5793","article-title":"MicroRNA-425 upregulation indicates better prognosis in younger acute myeloid leukemia patients undergoing chemotherapy","volume":"17","author":"Zhang","year":"2019","journal-title":"Oncol. Lett."},{"issue":"11","key":"10.1016\/j.semcancer.2023.03.009_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103350","article-title":"The long non-coding RNA CDK6-AS1 overexpression impacts on acute myeloid leukemia differentiation and mitochondrial dynamics","volume":"24","author":"Porcu","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.semcancer.2023.03.009_bib153","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/cells8080805","article-title":"Metabolic plasticity of acute myeloid leukemia","volume":"8","author":"Kreitz","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.semcancer.2023.03.009_bib154","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.807266","article-title":"Exploring the metabolic landscape of AML: from haematopoietic stem cells to myeloblasts and leukaemic stem cells","volume":"12","author":"Mesbahi","year":"2022","journal-title":"Front Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib155","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ccell.2018.08.016","article-title":"Subversion of systemic glucose metabolism as a mechanism to support the growth of leukemia cells","volume":"34","author":"Ye","year":"2018","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.semcancer.2023.03.009_bib156","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.molcel.2016.08.014","article-title":"PHD3 loss in cancer enables metabolic reliance on fatty acid oxidation via deactivation of ACC2","volume":"63","author":"German","year":"2016","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.semcancer.2023.03.009_bib157","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1158\/0008-5472.CAN-16-1645","article-title":"Bone marrow adipocytes facilitate fatty acid oxidation activating AMPK and a transcriptional network supporting survival of acute monocytic leukemia cells","volume":"77","author":"Tabe","year":"2017","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib158","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40170-021-00253-w","article-title":"Mitochondrial metabolism as a target for acute myeloid leukemia treatment","volume":"9","author":"Panina","year":"2021","journal-title":"Cancer Metab."},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-021-01416-w","article-title":"Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia","volume":"36","author":"de Beauchamp","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib160","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/bloodadvances.2020002981","article-title":"The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker","volume":"5","author":"Lo Presti","year":"2021","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib161","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3343\/alm.2016.36.2.101","article-title":"Clinicopathological Implications of Mitochondrial Genome Alterations in Pediatric Acute Myeloid Leukemia","volume":"36","author":"Kang","year":"2016","journal-title":"Ann. Lab Med"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib162","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12943-019-0952-z","article-title":"A critical role of epigenetic inactivation of miR-9 in EVI1(high) pediatric AML","volume":"18","author":"Mittal","year":"2019","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2023.03.009_bib163","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.3324\/haematol.2019.225953","article-title":"EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase","volume":"105","author":"Saito","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2023.03.009_bib164","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fgene.2018.00405","article-title":"Epigenetic-transcriptional regulation of fatty acid metabolism and its alterations in leukaemia","volume":"9","author":"Maher","year":"2018","journal-title":"Front Genet"},{"issue":"3","key":"10.1016\/j.semcancer.2023.03.009_bib165","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.cell.2012.06.027","article-title":"Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Ppargamma","volume":"150","author":"Qiang","year":"2012","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib166","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1530\/JME-14-0066","article-title":"Inhibition of HDAC3 promotes ligand-independent PPARgamma activation by protein acetylation","volume":"53","author":"Jiang","year":"2014","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.semcancer.2023.03.009_bib167","first-page":"12","article-title":"Metabolic regulation of epigenetic modifications and cell differentiation in cancer","author":"Saggese","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2023.03.009_bib168","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.768996","article-title":"Metabolic fuel for epigenetic: nuclear production meets local consumption","volume":"12","author":"Boon","year":"2021","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib169","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cmet.2012.06.001","article-title":"Metabolic regulation of epigenetics","volume":"16","author":"Lu","year":"2012","journal-title":"Cell Metab."},{"issue":"10","key":"10.1016\/j.semcancer.2023.03.009_bib170","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/leu.2011.133","article-title":"IDH1 and IDH2 mutations in pediatric acute leukemia","volume":"25","author":"Andersson","year":"2011","journal-title":"Leukemia"},{"issue":"7274","key":"10.1016\/j.semcancer.2023.03.009_bib171","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.semcancer.2023.03.009_bib172","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.semcancer.2023.03.009_bib173","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","journal-title":"EMBO Rep."},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib174","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40880-018-0302-3","article-title":"Metabolic recoding of epigenetics in cancer","volume":"38","author":"Wang","year":"2018","journal-title":"Cancer Commun."},{"issue":"7390","key":"10.1016\/j.semcancer.2023.03.009_bib175","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"issue":"5929","key":"10.1016\/j.semcancer.2023.03.009_bib176","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","article-title":"Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1","volume":"324","author":"Tahiliani","year":"2009","journal-title":"Science"},{"issue":"7347","key":"10.1016\/j.semcancer.2023.03.009_bib177","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature09934","article-title":"Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells","volume":"473","author":"Wu","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib178","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/leu.2010.243","article-title":"TET2 mutations in childhood leukemia","volume":"25","author":"Langemeijer","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.semcancer.2023.03.009_bib179","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.semcancer.2023.03.009_bib180","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1038\/leu.2011.142","article-title":"Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups","volume":"25","author":"Damm","year":"2011","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.semcancer.2023.03.009_bib181","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2014-09-600643","article-title":"Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target","volume":"125","author":"Mussai","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semcancer.2023.03.009_bib182","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-12-2641","article-title":"ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance","volume":"19","author":"Huang","year":"2013","journal-title":"Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.semcancer.2023.03.009_bib183","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3390\/cancers7030869","article-title":"Next-generation sequencing approaches in cancer: where have they brought us and where will they take us?","volume":"7","author":"LeBlanc","year":"2015","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.semcancer.2023.03.009_bib184","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1158\/2643-3230.BCD-21-0010","article-title":"Mutation signatures of pediatric acute myeloid leukemia and normal blood progenitors associated with differential patient outcomes","volume":"2","author":"Brandsma","year":"2021","journal-title":"Blood Cancer Disco"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib185","doi-asserted-by":"crossref","first-page":"82","DOI":"10.21037\/atm-21-6681","article-title":"Comparison of multi-omics results between patients with acute myeloid leukemia with long-term survival and healthy controls","volume":"10","author":"Song","year":"2022","journal-title":"Ann. Transl. Med"},{"issue":"5","key":"10.1016\/j.semcancer.2023.03.009_bib186","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3892\/br.2020.1353","article-title":"Panel-based next-generation sequencing facilitates the characterization of childhood acute myeloid leukemia in clinical settings","volume":"13","author":"Ishida","year":"2020","journal-title":"Biomed. Rep."},{"issue":"5","key":"10.1016\/j.semcancer.2023.03.009_bib187","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0022034509335868","article-title":"Epigenetics: connecting environment and genotype to phenotype and disease","volume":"88","author":"Barros","year":"2009","journal-title":"J. Dent. Res"},{"key":"10.1016\/j.semcancer.2023.03.009_bib188","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.666470","article-title":"Targeted next-generation sequencing of circulating tumor DNA, bone marrow, and peripheral blood mononuclear cells in pediatric AML","volume":"11","author":"Ruan","year":"2021","journal-title":"Front Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2023.03.009_bib189","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/gcc.22443","article-title":"ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)\/ RUNX1-RUNX1T1 and associated with a better prognosis","volume":"56","author":"Yamato","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2023.03.009_bib190","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s41375-017-0003-y","article-title":"Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML","volume":"32","author":"Zampini","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.semcancer.2023.03.009_bib191","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.exphem.2015.04.002","article-title":"Low-level GATA2 overexpression promotes myeloid progenitor self-renewal and blocks lymphoid differentiation in mice","volume":"43","author":"Nandakumar","year":"2015","journal-title":"Exp. Hematol."},{"issue":"5","key":"10.1016\/j.semcancer.2023.03.009_bib192","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/s41375-021-01242-0","article-title":"Single base substitution mutational signatures in pediatric acute myeloid leukemia based on whole genome sequencing","volume":"35","author":"Gunnarsson","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib193","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/15592294.2016.1267886","article-title":"The epigenetic regulation of Dicer and microRNA biogenesis by Panobinostat","volume":"12","author":"Hoffend","year":"2017","journal-title":"Epigenetics"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib194","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib195","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/leu.2016.282","article-title":"Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy","volume":"31","author":"Uy","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib196","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/MOH.0000000000000626","article-title":"Genetic heterogeneity and clonal evolution in acute myeloid leukemia","volume":"28","author":"Romer-Seibert","year":"2021","journal-title":"Curr. Opin. Hematol."},{"issue":"8","key":"10.1016\/j.semcancer.2023.03.009_bib197","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-018-0115-6","article-title":"Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib","volume":"24","author":"Quek","year":"2018","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib198","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41467-018-08263-x","article-title":"Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.semcancer.2023.03.009_bib199","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1182\/bloodadvances.2019000404","article-title":"Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia","volume":"3","author":"Shiba","year":"2019","journal-title":"Blood Adv."},{"issue":"23","key":"10.1016\/j.semcancer.2023.03.009_bib200","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib201","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.stem.2018.01.011","article-title":"Clonal hematopoiesis and evolution to hematopoietic malignancies","volume":"22","author":"Bowman","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.semcancer.2023.03.009_bib202","first-page":"13","article-title":"Single-cell sequencing: biological insight and potential clinical implications in pediatric leukemia","author":"Alpar","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2023.03.009_bib203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/cells9112493","article-title":"Molecular mechanisms of resistance to FLT3 inhibitors in acute myeloid leukemia: ongoing challenges and future treatments","volume":"9","author":"Scholl","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib204","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MOP.0000000000000855","article-title":"Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy","volume":"32","author":"Elgarten","year":"2020","journal-title":"Curr. Opin. Pedia"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2353\/jmoldx.2010.090054","article-title":"Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia","volume":"12","author":"Gulley","year":"2010","journal-title":"J. Mol. Diagn."},{"issue":"7","key":"10.1016\/j.semcancer.2023.03.009_bib206","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.semcancer.2023.03.009_bib207","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","article-title":"Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012","volume":"32","author":"Rasche","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.semcancer.2023.03.009_bib208","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1038\/sj.leu.2403924","article-title":"Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials","volume":"19","author":"Gibson","year":"2005","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib209","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib210","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12012-015-9307-1","article-title":"Anthracycline-related cardiotoxicity in patients with acute myeloid leukemia and down syndrome: a literature review","volume":"16","author":"Hefti","year":"2016","journal-title":"Cardiovasc Toxicol."},{"issue":"27","key":"10.1016\/j.semcancer.2023.03.009_bib211","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib212","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41375-020-1003-x","article-title":"Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network","volume":"35","author":"Gu","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.semcancer.2023.03.009_bib213","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood-2017-09-803809","article-title":"A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium","volume":"131","author":"Sun","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.semcancer.2023.03.009_bib214","article-title":"Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia","volume":"65","author":"Tamura","year":"2018","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.semcancer.2023.03.009_bib215","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13148-017-0411-x","article-title":"A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML","volume":"9","author":"Gore","year":"2017","journal-title":"Clin. Epigenetics"},{"issue":"21","key":"10.1016\/j.semcancer.2023.03.009_bib216","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1002\/cncr.33156","article-title":"Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia","volume":"126","author":"Karol","year":"2020","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.semcancer.2023.03.009_bib217","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1080\/15384047.2015.1095406","article-title":"Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo","volume":"16","author":"Qi","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.semcancer.2023.03.009_bib218","first-page":"12","article-title":"Inhibition of methyltransferase DOT1L sensitizes to sorafenib treatment AML cells irrespective of MLL-rearrangements: a novel therapeutic strategy for pediatric AML","author":"Lonetti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semcancer.2023.03.009_bib219","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.leukres.2017.05.004","article-title":"Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia","volume":"58","author":"Gopalakrishnapillai","year":"2017","journal-title":"Leuk. Res"},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib220","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrm3772","article-title":"Metabolic requirements for the maintenance of self-renewing stem cells","volume":"15","author":"Ito","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"27","key":"10.1016\/j.semcancer.2023.03.009_bib221","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","article-title":"Collaborative efforts driving progress in pediatric acute myeloid leukemia","volume":"33","author":"Zwaan","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2023.03.009_bib222","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1002\/jcb.26899","article-title":"Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a\/hexokinase 2 pathway","volume":"119","author":"Zhang","year":"2018","journal-title":"J. Cell Biochem"},{"key":"10.1016\/j.semcancer.2023.03.009_bib223","doi-asserted-by":"crossref","first-page":"48","DOI":"10.21037\/sci.2017.05.04","article-title":"Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia","volume":"4","author":"Chen","year":"2017","journal-title":"Stem Cell Invest."},{"issue":"3","key":"10.1016\/j.semcancer.2023.03.009_bib224","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1182\/bloodadvances.2019000919","article-title":"Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations","volume":"4","author":"Tarver","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2023.03.009_bib225","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.leukres.2016.10.004","article-title":"Synergistic cell death in FLT3-ITD positive acute myeloid leukemia by combined treatment with metformin and 6-benzylthioinosine","volume":"50","author":"Sabnis","year":"2016","journal-title":"Leuk. Res"},{"issue":"1\u20132","key":"10.1016\/j.semcancer.2023.03.009_bib226","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41417-018-0071-9","article-title":"Overexpression of PDK2 and PDK3 reflects poor prognosis in acute myeloid leukemia","volume":"27","author":"Cui","year":"2020","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib227","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.18632\/oncotarget.6366","article-title":"Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth","volume":"7","author":"Qin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2023.03.009_bib228","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2018.04.004","article-title":"Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway","volume":"69","author":"Grohmann","year":"2018","journal-title":"Leuk. Res"},{"issue":"3","key":"10.1016\/j.semcancer.2023.03.009_bib229","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/leu.2017.281","article-title":"Targeting the vulnerability to NAD(+) depletion in B-cell acute lymphoblastic leukemia","volume":"32","author":"Takao","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib230","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ijc.27726","article-title":"Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells","volume":"132","author":"Thakur","year":"2013","journal-title":"Int J. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2023.03.009_bib231","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/bloodadvances.2018024182","article-title":"Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia","volume":"3","author":"Mitchell","year":"2019","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib232","article-title":"New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology","volume":"3","author":"Roulston","year":"2016","journal-title":"Mol. Cell Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2023.03.009_bib233","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semcancer.2023.03.009_bib234","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"19","key":"10.1016\/j.semcancer.2023.03.009_bib235","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1182\/bloodadvances.2020002904","article-title":"Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial","volume":"4","author":"Voso","year":"2020","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib236","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/pbc.23394","article-title":"Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia","volume":"59","author":"Watt","year":"2012","journal-title":"Pedia Blood Cancer"},{"issue":"24","key":"10.1016\/j.semcancer.2023.03.009_bib237","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2011.34.7427","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed\/refractory leukemia","volume":"29","author":"Inaba","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2023.03.009_bib238","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fonc.2014.00055","article-title":"Molecular therapeutic approaches for pediatric acute myeloid leukemia","volume":"4","author":"Tasian","year":"2014","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib239","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.semcancer.2023.03.009_bib240","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2023.03.009_bib241","doi-asserted-by":"crossref","unstructured":"Lins M.M., Mello M.J.G., Ribeiro R.C., De Camargo B., de Fatima Pessoa Militao de Albuquerque M, Thuler LCS. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country. Ann Hematol. 2019;98(6):1403\u20131411.","DOI":"10.1007\/s00277-019-03661-7"},{"issue":"21","key":"10.1016\/j.semcancer.2023.03.009_bib242","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1200\/JCO.2004.01.191","article-title":"Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98","volume":"22","author":"Creutzig","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2023.03.009_bib243","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MPH.0000000000000490","article-title":"Early complications of hyperleukocytosis and leukapheresis in childhood acute leukemias","volume":"38","author":"Abla","year":"2016","journal-title":"J. Pedia Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2023.03.009_bib244","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/pbc.22931","article-title":"Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study","volume":"57","author":"Molgaard-Hansen","year":"2011","journal-title":"Pedia Blood Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib245","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/jnci\/djaa102","article-title":"LonG-term neurocognitive and psychosocial outcomes after acute myeloid leukemia: a childhood cancer survivor study report","volume":"113","author":"Stefanski","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.semcancer.2023.03.009_bib246","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jpeds.2012.11.038","article-title":"Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States","volume":"162","author":"Kavcic","year":"2013","journal-title":"J. Pedia"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib247","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.18.00313","article-title":"Occurrence of treatment-related cardiotoxicity and its impact on outcomes among children treated in the AAML0531 clinical trial: a report from the children's oncology group","volume":"37","author":"Getz","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.semcancer.2023.03.009_bib248","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.20.00158","article-title":"Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients","volume":"38","author":"Lehrnbecher","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.semcancer.2023.03.009_bib249","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41409-020-0869-6","article-title":"Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies","volume":"55","author":"Kalwak","year":"2020","journal-title":"Bone Marrow Transpl."},{"issue":"10","key":"10.1016\/j.semcancer.2023.03.009_bib250","article-title":"Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia","volume":"67","author":"Winters","year":"2020","journal-title":"Pedia Blood Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib251","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib252","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41467-021-21650-1","article-title":"Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics","volume":"12","author":"Velten","year":"2021","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.semcancer.2023.03.009_bib253","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.semcancer.2023.03.009_bib254","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2015.61.1947","article-title":"Clinical Impact of additional cytogenetic aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Munster Study Group","volume":"33","author":"Klein","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2023.03.009_bib255","first-page":"8","article-title":"Far from health: the bone marrow microenvironment in AML, a leukemia supportive shelter","author":"Sendker","year":"2021","journal-title":"Children"},{"key":"10.1016\/j.semcancer.2023.03.009_bib256","first-page":"13","article-title":"Redirecting the immune microenvironment in acute myeloid leukemia","author":"Sendker","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.semcancer.2023.03.009_bib257","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/16078454.2020.1858610","article-title":"Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia","volume":"26","author":"Chen","year":"2021","journal-title":"Hematology"},{"issue":"9","key":"10.1016\/j.semcancer.2023.03.009_bib258","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.3324\/haematol.2020.254623","article-title":"Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse","volume":"106","author":"Onecha","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.semcancer.2023.03.009_bib259","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/14737140.2021.1860763","article-title":"Measurable residual disease in pediatric acute myeloid leukemia: a systematic review","volume":"21","author":"Segerink","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"5","key":"10.1016\/j.semcancer.2023.03.009_bib260","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.molcel.2016.05.029","article-title":"Interplay between metabolism and epigenetics: a nuclear adaptation to environmental changes","volume":"62","author":"Etchegaray","year":"2016","journal-title":"Mol. Cell"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X23000500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X23000500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:08:57Z","timestamp":1760918937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X23000500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":260,"alternative-id":["S1044579X23000500"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2023.03.009","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenomic machinery regulating pediatric AML: Clonal expansion mechanisms, therapies, and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2023.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}